Summary
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor.
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) pipeline Target constitutes close to 30 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 8, 7, 2, 10 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders, Genito Urinary System And Sex Hormones, Infectious Disease, Central Nervous System and Immunology which include indications Thrombosis, Venous Thromboembolism, Bleeding And Clotting Disorders, Arterial Thrombosis, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Thromboembolic Disease, Atrial Fibrillation, Deep Vein Thrombosis (DVT), Hemophilia C (Factor XI Deficiency), Venous (Vein) Thrombosis, Acute Ischemic Stroke, Blood Coagulation, Coronavirus Disease 2019 (COVID-19), Inflammation, Ischemic Stroke, Myocardial Infarction, Neurology, Pulmonary Embolism, Sepsis, Stroke and Thromboembolism.
The latest report Coagulation Factor XI - Drugs In Development, 2022, outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
- The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects
- The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Overview
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Companies Involved in Therapeutics Development
Alphamab Oncology
Anthos Therapeutics Inc
Aronora Inc
Bayer AG
Bio Products Laboratory Ltd
Bioxodes SA
Bristol-Myers Squibb Co
Cambryn Biologics LLC
China Resources Pharmaceutical Group Ltd
eXithera Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
KLUS Pharma Inc
Merck & Co Inc
Mochida Pharmaceutical Co Ltd
Novartis AG
Ono Pharmaceutical Co Ltd
Regeneron Pharmaceuticals Inc
Shenzhen Salubris Pharmaceuticals Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Sirnaomics Ltd
Suzhou Ribo Life Sciences Co Ltd
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Drug Profiles
7300 Series - Drug Profile
Product Description
Mechanism Of Action
A-186 - Drug Profile
Product Description
Mechanism Of Action
History of Events
A-336 - Drug Profile
Product Description
Mechanism Of Action
AB-023 - Drug Profile
Product Description
Mechanism Of Action
History of Events
abelacimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
asundexian - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-962212 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-986209 - Drug Profile
Product Description
Mechanism Of Action
History of Events
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
EP-7041 - Drug Profile
Product Description
Mechanism Of Action
History of Events
fesomersen sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
IONIS-FXIRx - Drug Profile
Product Description
Mechanism Of Action
History of Events
Ir-CPI - Drug Profile
Product Description
Mechanism Of Action
History of Events
KN-060 - Drug Profile
Product Description
Mechanism Of Action
milvexian - Drug Profile
Product Description
Mechanism Of Action
History of Events
MK-2060 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MR-1007 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NIP-003 - Drug Profile
Product Description
Mechanism Of Action
ONO-7684 - Drug Profile
Product Description
Mechanism Of Action
History of Events
osocimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
REGN-9933 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SAL-0104 - Drug Profile
Product Description
Mechanism Of Action
SHR-2285 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SKB-336 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit Coagulation Factor XI for Bleeding and Clotting Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Factor XI for Bleeding And Clotting Disorders - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
SR-059 - Drug Profile
Product Description
Mechanism Of Action
STP-122G - Drug Profile
Product Description
Mechanism Of Action
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Products
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Discontinued Products
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Product Development Milestones
Featured News & Press Releases
Aug 28, 2022: Late-breaking results from phase 2 AXIOMATIC-SSP study of Milvexian, an investigational oral factor XIa inhibitor, show favorable antithrombotic profile in combination with dual antiplatelet therapy
Aug 25, 2022: Anthos therapeutics launches second phase 3 clinical trial of its dual-acting Factor XI inhibitor, abelacimab
Aug 23, 2022: Merck receives fast track designation from the U.S. FDA for MK-2060, an investigational anticoagulant therapy
Aug 22, 2022: Bayer to present data from cardiovascular portfolio, including a late-breaking presentation from new phase IIb data from PACIFIC Trial program for the oral factor XIa Inhibitor asundexian
Jul 29, 2022: Ionis reports positive Phase IIb data of fesomersen for thrombosis
Jul 28, 2022: Phase 2b studies of investigational selective coagulation modulator osocimab in patients with advanced renal disease completed
Jul 13, 2022: Four new sets of pre-clinical data further expands the evidence supporting abelacimab
Jul 11, 2022: Anthos Therapeutics announces that abelacimab has received FDA fast track designation for the treatment of thrombosis associated with cancer
Jun 13, 2022: Anthos Therapeutics to host discussion with global experts on the promise of Factor XI Inhibition at the 2022 BIO International Convention
May 05, 2022: Abelacimab: first factor XI inhibitor to enroll patients in a phase 3 clinical trial
Apr 11, 2022: Announcement of Haisco on obtaining the drug clinical trial approval notice for HSK36273
Apr 03, 2022: Bayer presents positive results from first Phase 2b trial on safety of asundexian in patients with atrial fibrillation
Mar 29, 2022: Bayer to present data on Asundexian at the American College of Cardiology's 71st Annual Scientific Session
Feb 10, 2022: Bayer receives FDA Fast Track Designation for asundexian stroke program
Jan 18, 2022: Haisco announces notice of acceptance for clinical trial application of HSK36273 for innovative drug injection
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Alphamab Oncology, 2022
Pipeline by Anthos Therapeutics Inc, 2022
Pipeline by Aronora Inc, 2022
Pipeline by Bayer AG, 2022
Pipeline by Bio Products Laboratory Ltd, 2022
Pipeline by Bioxodes SA, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Cambryn Biologics LLC, 2022
Pipeline by China Resources Pharmaceutical Group Ltd, 2022
Pipeline by eXithera Pharmaceuticals Inc, 2022
Pipeline by Ionis Pharmaceuticals Inc, 2022
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Pipeline by KLUS Pharma Inc, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Mochida Pharmaceutical Co Ltd, 2022
Pipeline by Novartis AG, 2022
Pipeline by Ono Pharmaceutical Co Ltd, 2022
Pipeline by Regeneron Pharmaceuticals Inc, 2022
Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, 2022
Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
Pipeline by Sirnaomics Ltd, 2022
Pipeline by Suzhou Ribo Life Sciences Co Ltd, 2022
Dormant Projects, 2022
Discontinued Products, 2022
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
